Xtant Medical - XTNT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.10
  • Forecasted Upside: 180.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.75
+0 (0.00%)

This chart shows the closing price for XTNT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Xtant Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XTNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XTNT

Analyst Price Target is $2.10
▲ +180.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Xtant Medical in the last 3 months. The average price target is $2.10, with a high forecast of $3.00 and a low forecast of $1.20. The average price target represents a 180.00% upside from the last price of $0.75.

This chart shows the closing price for XTNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Xtant Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/16/2024BTIG ResearchBoost TargetBuy ➝ Buy$2.00 ➝ $3.00
12/5/2023BTIG ResearchInitiated CoverageBuy$2.00
7/11/2023Craig HallumBoost Target$1.00 ➝ $1.20
4/26/2023Craig HallumInitiated CoverageBuy
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/29/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/28/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/28/2024

Current Sentiment

  • 3 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Xtant Medical logo
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.
Read More

Today's Range

Now: $0.75
Low: $0.72
High: $0.81

50 Day Range

MA: N/A

52 Week Range

Now: $0.75
Low: $0.60
High: $1.45

Volume

84,519 shs

Average Volume

133,507 shs

Market Capitalization

$97.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Xtant Medical?

The following Wall Street sell-side analysts have issued reports on Xtant Medical in the last twelve months: BTIG Research, Craig Hallum, and TheStreet.
View the latest analyst ratings for XTNT.

What is the current price target for Xtant Medical?

2 Wall Street analysts have set twelve-month price targets for Xtant Medical in the last year. Their average twelve-month price target is $2.10, suggesting a possible upside of 180.0%. BTIG Research has the highest price target set, predicting XTNT will reach $3.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $1.20 for Xtant Medical in the next year.
View the latest price targets for XTNT.

What is the current consensus analyst rating for Xtant Medical?

Xtant Medical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XTNT will outperform the market and that investors should add to their positions of Xtant Medical.
View the latest ratings for XTNT.

What other companies compete with Xtant Medical?

How do I contact Xtant Medical's investor relations team?

Xtant Medical's physical mailing address is 664 Cruiser Ln, BELGRADE, MT 59714-9719, United States. The medical device company's listed phone number is (406) 388-0480 and its investor relations email address is [email protected]. The official website for Xtant Medical is xtantmedical.com. Learn More about contacing Xtant Medical investor relations.